Eli Lilly & Company Foundation

What Eli Lilly & Company Foundation does

The Eli Lilly and Company Foundation is a private, Indianapolis-based philanthropic foundation established in 1968 that supports programs designed to improve patient outcomes and enhance quality of life. The Foundation operates as the charitable-giving arm of Eli Lilly and Company (NYSE: LLY), a 150-year-old global pharmaceutical company with 100+ patented medications across obesity, autoimmune, oncology, diabetes, neurology, and dermatology, and 10 Prix Galien Awards. Directly observable Foundation activity in the source data is limited to a single June 2026 commitment of $5 million, made jointly with Convatec, to Partners In Health to support non-communicable disease and chronic care programs in Rwanda, Peru, Malawi, and Sierra Leone.

The Foundation's strategic context is shaped by the parent company's significant 2026 activity, including the $7.8 billion acquisition of Centessa Pharmaceuticals (neuroscience and sleep medicine), FDA approval of Foundayo (orforglipron, the first oral GLP-1 weight-loss pill), the China NMPA approval and Innovent-led commercialization of Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia, and a multi-year Lilly Canada partnership with the Toronto Blue Jays. The parent also maintains LillyDirect, a direct-to-consumer pharmacy offering home delivery of authentic Lilly medicines, and partnerships with independent telehealth providers across dermatology, migraine, and sleep apnea.

Because the Foundation is grant-funded rather than revenue-generating, its business model consists of deploying contributed capital into nonprofit and public-health partnerships, with no disclosed commercial pricing, sales force, or product revenue of its own. The source data does not include Foundation-level financials, endowment size, employee headcount, or a portfolio of grant recipients; characterization of its scale, growth, and operational footprint is therefore limited and most observable activity is indirectly attributable through the parent.

Name

Eli Lilly & Company Foundation

Legal name

Eli Lilly and Company

Website

https://lilly.com

Company type

Public

Founded year

1876

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Eli Lilly and Company Foundation is a private 1968 Indianapolis-based philanthropic foundation that funds programs improving patient outcomes and quality of life, operating as the charitable arm of Eli Lilly and Company. Its only disclosed grant is a $5M 2026 commitment to Partners In Health for non-communicable disease care in resource-limited countries.

Ownership category

akta.pro rank

Product category

Philanthropic Foundation

NAICS

Grantmaking Foundations (813211), Grantmaking and Giving Services (81321), Other Grantmaking and Giving Services (813219)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

International Grantmaking & Development Foundations (BPAGAKAH), Grantmaking & Philanthropic Funds (Institutional Donors) (BPADAOAB)

Keywords

• Philanthropic grantmaking
• Healthcare foundation
• Non-communicable disease programs
• Global health equity
• Corporate charitable giving

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from prescription pharmaceutical products including GLP-1 medications for obesity, autoimmune treatments, cancer therapies, diabetes medications, and neurological treatments sold through pharmacy channels and healthcare providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

The Eli Lilly & Company Foundation is a private corporate foundation that provides philanthropic grants and funding to support programs designed to improve patient outcomes and enhance quality of life. Its documented grantmaking activity includes a $5 million joint commitment with Convatec to Partners In Health (PIH) to scale care models, train health workers, and strengthen health systems for non-communicable disease and chronic care in resource-limited countries (Rwanda, Peru, Malawi, and Sierra Leone). The Foundation operates as the charitable giving arm of Eli Lilly and Company.

Product overview

Eli Lilly & Company Foundation's product portfolio centers on LillyDirect, a digital health platform providing pharmacy services, telehealth connections, and clinical trial access. The platform offers condition-specific resources for Alzheimer's, cancer, dermatology, autoimmune diseases, sleep apnea, diabetes, and obesity, while connecting patients to healthcare providers. Complementing the digital platform is a portfolio of branded pharmaceutical products spanning multiple therapeutic areas: Kisunla (donanemab) for Alzheimer's disease; Zepbound and Mounjaro (tirzepatide) for diabetes and obesity; Taltz (ixekizumab) and EBGLYSS (lebrikizumab) for dermatology and autoimmune conditions; Olumiant (baricitinib) for rheumatoid arthritis and inflammatory diseases; Omvoh (mirikizumab) for inflammatory bowel disease; Jaypirca (pirtobrutinib) for hematologic malignancies; and Foundayo (orforglipron) as an oral GLP-1 obesity treatment. The company also provides patient support programs and clinical trial matching services.

Differentiator

Problem solved

Functional benefit

Brands

• Foundayo: Oral GLP-1 pill for weight loss approved by FDA in April 2026
• Taltz
• Zepbound
• EBGLYSS
• Jaypirca

Products and services

• Partners In Health (PIH) Grant Program Multi-year grantmaking program funding healthcare delivery, health worker training, and health system strengthening for non-communicable disease and chronic care in resource-limited countries. Awarded to nonprofit partner Partners In Health.

Quantifiable outcome

• Participants lost an average of 27 pounds compared to placebo in Foundayo clinical trials
• +3 more outcomes

Named customers1 record

Segments8 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• ConvatecminorStrategic or Co-development Partner · 9 June 2026Convatec and the Eli Lilly and Company Foundation committed $5 million to Partners In Health (PIH) to support healthcare projects in resource-limited settings, focusing on non-communicable diseases and chronic care. The funding aims to scale care models, train health workers, and strengthen health systems across several countries including Rwanda, Peru, Malawi, and Sierra Leone.
• Partners In Health (PIH)coreStrategic or Co-development Partner · 9 June 2026Healthcare nonprofit receiving $5 million commitment from Convatec and Eli Lilly and Company Foundation to support healthcare projects in resource-limited settings. Focus areas include non-communicable diseases and chronic care, with programs to scale care models, train health workers, and strengthen health systems in Rwanda, Peru, Malawi, and Sierra Leone.
• Toronto Blue JaysminorGTM or Marketing Partner · 8 April 2026Lilly Canada multi-year partnership with the Toronto Blue Jays to promote health and innovation, celebrating the Blue Jays' 50th season and Lilly's 150 years of scientific progress. Emphasizes shared values of perseverance and teamwork.
• Centessa PharmaceuticalscoreStrategic or Co-development Partner · 31 March 2026Lilly is acquiring Centessa Pharmaceuticals in a deal to expand Lilly's neuroscience and sleep medicine portfolio. Transaction involves cash consideration of up to $47 per share including contingent payments based on FDA approval milestones, with total equity value of approximately $7.8 billion.
• Innovent BiologicscoreChannel Partner/ Reseller/ Distributor · 1 March 2026Innovent Biologics received approval from China's National Medical Products Administration to commercialize Jaypirca (pirtobrutinib) in mainland China for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after prior BTK inhibitor therapy. Based on Phase 3 BRUIN CLL-321 trial showing significant PFS improvement.
• Fauna BiominorStrategic or Co-development Partner · 1 December 2023Strategic obesity discovery collaboration initiated in December 2023. Fauna Bio achieved a target designation milestone using its Convergence AI platform leveraging insights from hibernating mammals. The target represents a potential first-in-class approach to treating obesity and validates Fauna Bio's comparative genomics platform analyzing genomic data from over 450 mammal species.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bayer Foundation: Corporate foundation of Bayer funding health, nutrition, and education programs. Comparable scale and structure as a top-tier pharmaceutical corporate foundation with international reach.
• Novartis Foundation: Corporate foundation of Novartis focused on NCDs, cardiovascular disease, and health system strengthening in low/middle-income countries. Closely aligned with Lilly Foundation's stated PIH program focus.
• Pfizer Foundation: The corporate charitable arm of Pfizer, one of the world's largest pharmaceutical companies. Directly comparable as a pharma corporate foundation funding global health programs, health worker training, and NCD initiatives in low-resource settings.
• Bristol Myers Squibb Foundation: Corporate foundation of Bristol Myers Squibb funding health disparities and NCD programs globally. Comparable scope, geographic focus, and alignment with parent pharmaceutical R&D priorities.
• Johnson & Johnson Foundation: Corporate giving arm of Johnson & Johnson, funding global health, health workforce development, and community health programs. Directly comparable in scale, mission alignment, and program design.
• Merck Foundation (MSD): The corporate foundation of Merck & Co., focused on global health, oncology access, and capacity-building for healthcare providers in underserved settings. Directly comparable therapeutic-area focus and operating model to the Lilly Foundation.
• Roche Foundation: Corporate foundation of Roche funding health access, oncology, and humanitarian programs in resource-limited settings. Comparable operating model and global health mission.
• AstraZeneca Foundation: Corporate foundation of AstraZeneca focused on health equity, NCD prevention, and youth health. Directly comparable scope and grantmaking priorities in cardiovascular and metabolic disease.
• Abbott Fund: Corporate foundation of Abbott focused on global health, NCDs, and health system strengthening. Directly comparable as a healthcare company corporate foundation with international grantmaking programs.

Broad incumbents

• Bill & Melinda Gates Foundation: The largest philanthropic foundation globally, with significant NCD, global health, and health system strengthening programs in LMICs. Functions as a broader incumbent in the same funding space, often co-funding with corporate foundations like Lilly's.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xtwitter.com/EliLillyandCo
• YouTubeyoutube.com/user/EliLillyandCompany
• Facebookfacebook.com/elilillyandco
• LinkedInlinkedin.com/company/eli-lilly-and-company
• Instagraminstagram.com/elilillyco

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments32 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eli Lilly & Company Foundation